Compare iShares Core Growth Allocation ETF (AOR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Core Growth Allocation ETF trades at $70.08, while State Street SPDR S&P Biotech ETF trades at $158.89. Which is the better fit depends on your goals.
| AOR | XBI | |
|---|---|---|
52-Week High | $70.12 | $164.28 |
52-Week Low | $62.26 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, an iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% today. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF maintains a fixed 60/40 stock/bond allocation and rebalances semiannually with a low 0.20% fee. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
The ETF offers diversified exposure but faces risks from equity-bond correlation shifts and competition from pure equity funds. Analyst sentiment is mixed, balancing its simplicity against historical lagging returns. Key catalysts include fee waivers until December 2026 and semiannual rebalancing, but investors should weigh its conservative allocation against growth objectives.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
